Unknown

Dataset Information

0

Immune checkpoint inhibitors and radiosurgery for newly diagnosed melanoma brain metastases.


ABSTRACT: INTRODUCTION:Brain metastases are common in metastatic melanoma and radiosurgery is often utilized for local control. Immune checkpoint inhibitors (CPIs) play a central role in contemporary melanoma management; however, there is limited data exploring outcomes and potential toxicities for patients treated with CPIs and radiosurgery. METHODS:We retrospectively identified all consecutive cases of newly diagnosed melanoma brain metastases (MBM) treated with Gamma Knife radiosurgery at a single institution between 2012 and 2017, and included only patients that initiated CPIs within 8 weeks before or after radiosurgery. RESULTS:Thirty-eight patients were included with a median follow-up of 31.6 months. Two-year local control was 92%. Median time to out-of-field CNS and extra-CNS progression were 8.4 and 7.9 months, respectively. Median progression-free survival (PFS) was 3.4 months and median overall survival (OS) was not reached (NR). Twenty-five patients (66%) received anti-CTLA4 and 13 patients (34%) received anti-PD-1+/-anti-CTLA4. Compared with anti-CTLA4, patients that received anti-PD-1+/-anti-CTLA4 had significant improvements in time to out-of-field CNS progression (p?=?0.049), extra-CNS progression (p?=?0.015), and PFS (p?=?0.043), with median time to out-of-field CNS progression of NR vs. 3.1 months, median time to extra-CNS progression of NR vs. 4.4 months, and median PFS of 20.3 vs. 2.4 months. Six patients (16%) developed grade???2 CNS toxicities (grade 2: 3, grade 3: 3, grade 4/5: 0). CONCLUSIONS:Excellent outcomes were observed in patients that initiated CPIs within 8 weeks of undergoing radiosurgery for newly diagnosed MBM. There appears to be an advantage to anti-PD-1 or combination therapy compared to anti-CTLA4.

SUBMITTER: Robin TP 

PROVIDER: S-EPMC6931903 | biostudies-literature | 2018 Oct

REPOSITORIES: biostudies-literature

altmetric image

Publications


<h4>Introduction</h4>Brain metastases are common in metastatic melanoma and radiosurgery is often utilized for local control. Immune checkpoint inhibitors (CPIs) play a central role in contemporary melanoma management; however, there is limited data exploring outcomes and potential toxicities for patients treated with CPIs and radiosurgery.<h4>Methods</h4>We retrospectively identified all consecutive cases of newly diagnosed melanoma brain metastases (MBM) treated with Gamma Knife radiosurgery a  ...[more]

Similar Datasets

| S-EPMC6213912 | biostudies-literature
| S-EPMC5030143 | biostudies-literature
| S-EPMC10252066 | biostudies-literature
| S-EPMC7145582 | biostudies-literature
| S-EPMC7839060 | biostudies-literature
| S-EPMC6061393 | biostudies-literature
| S-EPMC7426188 | biostudies-literature
| S-EPMC9256020 | biostudies-literature
| S-EPMC6094677 | biostudies-literature
| S-EPMC8797499 | biostudies-literature